Xortx announces submission of orphan drug designation request for xrx-008 program to treat autosomal dominant kidney disease

Calgary, alberta, feb. 01, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce it submitted an orphan drug designation (“odd”) request to the us food and drug administration (“fda”) for the xrx-008 program for the treatment of autosomal dominant polycystic kidney disease (“adpkd”).   xortx anticipates updates regarding the odd application and will provide announcements as information becomes available.
XRTX Ratings Summary
XRTX Quant Ranking